DIABETES AND ENDOCRINE PANCREAS II: Edited by Peter A. GottliebAdverse events associated with immune checkpoint inhibitors: a new era in autoimmune diabetesAkturk, Halis Kaan; Michels, Aaron W.Author Information Barbara Davis Center for Diabetes, University of Colorado, School of Medicine, Aurora, Colorado, USA Correspondence to Halis Kaan Akturk, MD, Assistant Professor of Medicine and Pediatrics, Barbara Davis Center for Diabetes, University of Colorado, 1775 Aurora Ct. Room 1318, Aurora, CO 80045, USA. Tel: +1 303 724 0467; e-mail: Halis.firstname.lastname@example.org Current Opinion in Endocrinology & Diabetes and Obesity: August 2020 - Volume 27 - Issue 4 - p 187-193 doi: 10.1097/MED.0000000000000546 Buy Metrics Abstract Purpose of review To summarize a new form of autoimmune diabetes as an adverse event of specific cancer immunotherapies. Immune checkpoint inhibitors are revolutionary treatments in advanced cancers; however, they can cause type 1 diabetes following treatment with these state-of-the-art therapies. Recent findings A review of the literature showed that this new form of autoimmune diabetes has significant similarities with childhood-onset type 1 diabetes but also some distinctions. It frequently presents with severe diabetic ketoacidosis and almost half of the patients have type 1 diabetes-associated antibodies at presentation. Rapid loss of residual beta-cell function with a lack of honeymoon phase is typical. Certain human leukocyte antigen risk genes for prototypical type 1 diabetes that develops in children and young adults are also commonly found in patients with immune checkpoint inhibitor-induced type 1 diabetes. Summary Immune checkpoint inhibitor-induced type 1 diabetes presenting with diabetic ketoacidosis is a life-threatening adverse event of cancer immunotherapy. Healthcare providers should be aware of this adverse event to prevent morbidity and mortality related to diabetic ketoacidosis. Developing guidelines to identify and monitor risk groups are of utmost importance. Copyright © 2020 Wolters Kluwer Health, Inc. All rights reserved.